Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 294

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo‐controlled clinical trial

SOLANKI, PRASHANT, CHAWLA, ATUL, GARG, RAMESH, GUPTA, RAJIV, JAIN, MONIKA, SARIN, SHIV K · 2003 · Journal of Gastroenterology and Hepatology

Abstract

Background and Aim: Hepatorenal syndrome (HRS) occurs in about 18% of cirrhotic patients with ascites and is characterized by intense renal vasoconstriction, low glomerular filtration rate and preserved tubular function and normal renal histology. The aim of the present study was to examine the effects of terlipressin on renal function, systemic hemodynamics and clinical outcome in patients with HRS. Methods: The study was a randomized controlled single‐blind trial. We randomly assigned 24 consecutive patients with HRS to treatment with terlipressin 1 mg i.v. at 12‐h intervals (group A; n = 12) or placebo at 12‐h intervals (group B; n = 12). The end‐point of the study was improvement in renal functions defined as reversal of HRS and survival at 15 days. Results: The two groups were comparable at baseline. After treatment with terlipressin, urine output significantly (P < 0.05) increased progressively in group A (day 4, 960 ± 40 mL/24 h; day 8, 1068 ± 56 mL/24 h) compared with group B (day 4, 451 ± 40 mL/24 h; day 8, 291 ± 45 mL/24 h). Creatinine clearance improved (P < 0.05) in group A (day 4, 20.2 ± 2.1 mL/min; day 8, 35 ± 2.8 mL/min) compared with group B (day 4, 11.3 ± 1.3 mL/min; day 8, 9.3 ± 1.7 mL/min). Serum creatinine decreased in group A but not in group B (day 8, 1.6 ± 0.01 compared with 3.9 ± 0.26, P < 0.05). Mean arterial pressure increased significantly (P < 0.05) in group A. Terlipressin administration was associated with transient self‐limiting side‐effects including crampy abdominal pain in two patients and cardiac arrhythmias in three patients. Five of the 12 patients survived in group A compared with none in group B at day 15 (P < 0.05) and all survivors had reversal of HRS. Conclusion: In patients with HRS, terlipressin significantly improved renal functions and systemic hemodynamics, and showed a trend towards better clinical outcome. The drug merits further evaluation with different dosages and longer schedules.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1440-1746.2003.02934.x

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 294

Metadata

Authors
SOLANKI, P., CHAWLA, A., GARG, R., GUPTA, R., JAIN, M., & SARIN, S. K.
Venue
Journal of Gastroenterology and Hepatology
Publisher
Wiley
Published
2003-01-24
Volume
18
Issue
2
Pages
152-156
ISSN
  • 0815-9319 (ISSN-L)
  • 1440-1746
OpenAlex
W2131903288
Cited by
294
References
10
FWCI
9.18
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo‐controlled clinical trial. https://app.cochat.ai/papers/10.1046/j.1440-1746.2003.02934.x
The paper
SOLANKI, P., CHAWLA, A., GARG, R., GUPTA, R., JAIN, M., & SARIN, S. K. (2003). Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology. https://doi.org/10.1046/j.1440-1746.2003.02934.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.